Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
Psychedelic Alpha’s Charles Bliss speaks with Chris Timmermann, Research Fellow in Neuroscience, Meditation and Psychedelics at University College London, about why understanding and integrating psychedelic experiences may be just as vital for personal growth as for treating mental illness.
We cover Beckley Psytech and atai Life Sciences’ conference call this morning, where company executives provided further details on the Phase 2b readout of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression and took aim at their closest competitor’s model.
This morning, Beckley Psytech shares topline data from its Phase 2b study of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression (TRD). The study, the largest of the drug to date, printed positive results, with a significant and rapid antidepressant effect and favourable safety profile. Here, we take a closer look at the results and share our quick-take analysis with reference to GH Research’s similar Phase 2b study.
Psychedelic Alpha’s Josh Hardman sits down with Beckley Psytech CEO Cosmo Feilding-Mellen and Chief Scientific and Medical Officer Rob Conley to discuss today’s topline results from the company’s Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression (TRD).
This is the second of a two-part series that looks at how people are reacting to Compass Pathways’ first readout from its Phase 3 program of psilocybin for treatment-resistant depression. Here, we turn to industry reactions.
RFK Jr. Envisages Psychedelics Access ‘Within 12 Months’ • Psychedelics in Washington: FDA, VA, and New Political Signals • Lykos Therapeutics’ New CEO and CMO, Amy Emerson Joins Board • New Zealand Approves First Psilocybin Prescriber • DEA Judge Recommends Schedule I Placement for DOI and DOC • and more…
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
Archived versions of our Psychedelic News Feed.
This is an archived version of our Psychedelic News Feed, from September 2 to December 29, 2024.
This is an archived version of our Psychedelic News Feed, from March 4, 2024 – September 1, 2024.
A special version of our Psychedelic News Feed to mark April 1st, 2024.
This is an archived version of our Psychedelic News Feed, from February 5 2024 – March 3 2024.
This is an archived version of our Psychedelic News Feed, from January 8 2024 – February 4 2024.
This is an archived version of our Psychedelic News Feed, from December 11 2023 – January 7 2024.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
